{'fraction_non_alphanumeric': 0.03420523138832998, 'fraction_numerical': 0.01609657947686117, 'mean_word_length': 5.821917808219178, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee

The identification of new therapies for high‐risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high‐risk hepatoblastoma.